Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical (NASDAQ: LFCR) reported fourth quarter revenues of $35.7M and transition-period revenue of $75.5M for the seven months ended Dec 31, 2025, a 20% increase year-over-year. Gross profit margin improved to 31.4%, operating expenses fell 31%, and Adjusted EBITDA was $13.1M. The company signed five new programs in 2025, launched a new ERP in Jan 2026, ended the quarter with ~$38.9M liquidity, and issued 2026 guidance of $120–$125M revenue and $20.5–$25M Adjusted EBITDA.
Lifecore Biomedical (NASDAQ: LFCR) will participate in the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum on March 17–18, 2026. Management, including Mr. Josephs, will host a fireside chat at 9:00–9:35am ET on March 17 and will meet with investors.
A live webcast of the fireside chat will be accessible via Lifecore’s Investor Events & Presentations page, with a replay available on the company website after the conference.
Lifecore Biomedical (NASDAQ: LFCR) will report fourth quarter and transition period results for the period ended December 31, 2025 on Monday, March 16, 2026 before the market opens.
A live webcast with senior management will begin at 8:30 a.m. Eastern to discuss results; a replay will be available on the company’s Investor Events & Presentations page for 30 days.
Lifecore Biomedical (NASDAQ: LFCR) signed a development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid formulation intended for use with Indomo’s ClearPen™ intradermal self-injection device. Lifecore will supply batches to support planned studies and prepare DT-001 for anticipated Phase 2 clinical trials in 2026.
The agreement expands Lifecore’s work beyond ophthalmics into device-enabled injectable therapeutics and continues a prior collaboration on formulation and process optimization for DT-001.
Lifecore Biomedical (NASDAQ: LFCR) will participate in DCAT Week 2026, March 23-26, 2026, in New York City. Lifecore's team will host customers and prospective partners to discuss development and manufacturing solutions for injectable programs. Meetings are available by contacting cdmo@lifecore.com.
Lifecore Biomedical (NASDAQ: LFCR) announced that on January 14, 2026 its compensation committee approved inducement equity grants for two newly hired employees under the company’s Equity Inducement Plan.
The grants consist of 1,738 restricted stock units (RSUs) and stock options covering an aggregate 8,775 shares. RSUs vest and settle on the third anniversary of the grant subject to continued employment. Options have an exercise price equal to Fair Market Value on the grant date, vest 1/3 after one year then 1/36 monthly thereafter, and expire after seven years.
Lifecore Biomedical (NASDAQ: LFCR) announced it will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI) as part of Nasdaq's annual index reconstitution. The inclusion is expected to be effective prior to market open on Monday, December 22, 2025.
The Nasdaq Biotechnology Index tracks Nasdaq-listed securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is calculated using a modified capitalization-weighted methodology. Constituents are selected once annually in December and must meet eligibility requirements including minimum market capitalization, average daily trading volume, and public company seasoning.
Lifecore Biomedical (NASDAQ: LFCR) signed a CDMO master services agreement on Dec 17, 2025 with a new large multinational pharmaceutical customer to provide development services and tech transfer for an injectable pharmaceutical product.
The program contemplates transferring commercial supply from overseas to Lifecore facilities, and Lifecore expects to become the commercial supplier once transfer and regulatory requirements are satisfied. Based on current commercial revenues for the program, the partner could become one of Lifecore’s top five commercial customers. This is Lifecore’s second multinational agreement in the past three months.
Lifecore Biomedical (NASDAQ: LFCR) said it will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.
Company management, including Paul Josephs (chief executive officer) and Ryan Lake (chief financial officer), are scheduled to participate in 1-on-1 meetings during the conference.
Lifecore Biomedical (NASDAQ: LFCR) will participate in two investor conferences in November 2025: the Jefferies 2025 Global Healthcare Conference in London and the Stephens Annual Investment Conference in Nashville. Paul Josephs, president and CEO, will deliver a corporate presentation and take part in investor meetings at Jefferies on Nov 18, 2025 at 9:30 a.m. GMT (4:30 a.m. ET) and will be a featured fireside chat speaker at Stephens on Nov 20, 2025 at 9:00 a.m. CT. Management will hold 1-on-1 meetings across both events (Nov 17–20 and Nov 18–20 respectively). Webcasts of both sessions will be available live and as replays via Lifecore’s Investor Events & Presentations page at https://ir.lifecore.com/events-presentations.